martes, 17 de noviembre de 2026

iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) (+++...)

https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems?utm_medium=email&utm_source=govdelivery iPLEDGE REMS Modifications Have Been Implemented and Are Live for Isotretinoin, a Medication for Severe Acne The iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) modifications were implemented yesterday, November 15, 2026. The iPLEDGE REMS is a safety program to mitigate the risk of isotretinoin, which can result in harm to fetal development. Isotretinoin is approved to treat severe nodular acne that has not responded to other treatments in non-pregnant patients 12 years and older. The modifications aim to minimize the burden on patients, prescribers, and pharmacies while maintaining the safe use of isotretinoin. Important information is summarized below. Important information for patients: Enrolled patients do not need to re-enroll in the iPLEDGE REMS and can continue using the REMS system through their existing accounts. Prior to starting treatment with isotretinoin, patients must complete the required pregnancy tests in a medical setting. If permitted by a prescriber, patients may complete subsequent monthly pregnancy tests outside of a medical setting (e.g., using home pregnancy tests) during and after treatment with isotretinoin. If a person who can get pregnant does not pick up their prescription within 7 days of their last negative pregnancy test, a repeat pregnancy test may be done immediately without an additional waiting period. https://ipledgeprogram.com/#Main Important information for prescribers: Prescribers do not need to re-enroll or re-certify in the iPLEDGE REMS with this modification and can continue using the REMS system through their existing accounts and established workflows. Prescribers should continue to follow existing annual re-certification timelines. Prescribers do not need to update or change the assigned patient categories for enrolled/active patients. Prior to starting treatment with isotretinoin, patients must complete the required pregnancy tests in a medical setting. Prescribers may opt to allow patients to complete subsequent monthly pregnancy tests outside of a medical setting (e.g., using home pregnancy tests) during and after treatment. Prescribers will need to establish processes and procedures to minimize misinterpretation and falsification of pregnancy tests that patients complete outside of a medical setting. If a person who can get pregnant does not pick up their prescription within 7 days of their last negative pregnancy test, a repeat pregnancy test may be done immediately without an additional waiting period. If the patient has not started isotretinoin, the repeat pregnancy test must be done in a medical setting. Patients who cannot get pregnant must be counseled at enrollment. Monthly documentation of counseling in the iPLEDGE REMS for patients who cannot get pregnant is no longer required. Prescribers should reinforce counseling throughout the course of treatment. https://ipledgeprogram.com/#Main Important information for pharmacies: Pharmacy-authorized representatives do not need to re-enroll or re-certify in the iPLEDGE REMS with this modification and can continue using the REMS system through their existing accounts and established workflows. Pharmacy-authorized representatives should continue to follow existing annual re-certification timelines. There is no longer a 30-day prescription window for patients who cannot get pregnant. Pharmacies may need to adapt their workflow practices to ensure that, if a patient does not pick up the prescription, the authorization is reversed in the REMS and the prescription is returned to stock. Clarifying language was added to the REMS to communicate that pharmacy staff training is required annually and the certified pharmacy’s authorized representative should maintain records of training completion. https://ipledgeprogram.com/#Main https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-ipledge-rems?utm_medium=email&utm_source=govdelivery

No hay comentarios:

Publicar un comentario